Subscribe   RSS Contact Us

New Memorandum Spells Out FDA’s First Amendment Position on Off-label Use Promotion

Jan. 20, 2017 – The FDA effectively delayed any prompt action on new guidance covering the promotion of unapproved or ... read more

Marketing Tax Provision Escapes Senate Vote

Jan. 13, 2017 – An amendment introduced by Sen. Al Franken (D-Minn.) to eliminate the tax deduction for drug marketing ... read more

FDA Will Study Consumer and HCP Ability to Identify Deceptive Drug Promotion

Jan. 4, 2017 – The FDA will examine whether consumers and health care professionals (HCPs) can identify deceptive claims in ... read more

OPDP Cites Two Companies for YouTube Videos Featuring INDs

Jan. 3, 2017 – In its last blast of 2016, the FDA’s Office of Prescription Drug Promotion (OPDP) sent Untitled ... read more

OPDP Sends Two Letters Citing Major Statement Treatment in TV Ad Claims

Dec. 15, 2016 – Television ads allegedly making false and misleading claims about the risks associated with their products were ... read more

Previous Next

Next OPDP Webinar Will Address Five Months of Enforcement Actions

May 14, 2013 — The FDA’s Office of Prescription Drug Promotion (OPDP) will be holding an Enforcement Webinar May 16, from 11:30 a.m. to 12 p.m. (ET), to give stakeholders an opportunity to directly communicate with OPDP staff about clarifications or questions concerning recent enforcement letters issued by OPDP.  This particular webinar will cover the six Untitled Letters issued by OPDP from November 2012 through March 2013.

These focused Webinars “support OPDP’s mission to protect the public health by assuring that prescription drug information is truthful, balanced, and accurately communicated,” according to OPDP. Viewers can begin submitting questions 30 minutes prior to the Webinar start time.

Meeting details are listed below:

FOR WEB:

To join the meeting:

https://collaboration.fda.gov/ddmac34

FOR AUDIO:

Conference Number(s): 877-231-0558

Participant Code: 9291